ストックスクリーナーアプリを入手
8.08
6.26%
-0.54
アフターアワーズ：
8.08
前日終値:
$8.62
開ける：
$8.27
24時間の取引高:
2.52M
Relative Volume:
2.65
時価総額：
$1.55B
収益：
$53.61M
当期純損益:
$-142.52M
株価収益率:
-7.2793
EPS:
-1.11
ネットキャッシュフロー:
$-141.83M
1週間 パフォーマンス:
-19.76%
1か月 パフォーマンス:
-23.56%
6か月 パフォーマンス:
-1.46%
1年 パフォーマンス:
+30.96%
1日の値動き範囲:
$7.92
$8.40
1週間の範囲:
$7.92
$10.91
52週間の値動き範囲:
$4.25
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
WVE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
WVE
Wave Life Sciences Ltd
|
8.08 | 1.55B | 53.61M | -142.52M | -141.83M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-25 | 開始されました | Jefferies | Buy |
| 2024-10-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-09-27 | 再開されました | JP Morgan | Overweight |
| 2024-09-19 | 開始されました | B. Riley Securities | Buy |
| 2024-09-09 | 開始されました | JP Morgan | Overweight |
| 2024-05-15 | 開始されました | Wells Fargo | Overweight |
| 2023-12-19 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 開始されました | Raymond James | Outperform |
| 2023-05-24 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | 開始されました | Guggenheim | Buy |
| 2019-07-15 | 開始されました | Cowen | Market Perform |
| 2019-04-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-08-07 | 開始されました | Stifel | Buy |
| 2018-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-19 | 繰り返されました | Mizuho | Buy |
| 2017-02-15 | 開始されました | H.C. Wainwright | Buy |
| 2016-11-10 | 再開されました | Leerink Partners | Outperform |
| 2015-12-07 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-12-07 | 開始されました | Jefferies | Buy |
| 2015-12-07 | 開始されました | Leerink Partners | Outperform |
| 2015-12-07 | 開始されました | Sun Trust Rbsn Humphrey | Buy |
すべてを表示
Wave Life Sciences Ltd (WVE) 最新ニュース
Wave Life Sciences’ SWOT analysis: RNA editing pioneer faces challenges in genetic medicine stock - Investing.com India
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Nasdaq
Promising Genomics & Synthetic Biology Stocks to Consider in 2025 - Yahoo Finance
HC Wainwright Reaffirms “Buy” Rating for Wave Life Sciences (NASDAQ:WVE) - Defense World
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531 (NASDAQ:WVE) - Seeking Alpha
WAVE Life Sciences stock holds buy rating, $22 target from H.C. Wainwright - Investing.com Australia
Wave Life Sciences (WVE) Stock Jumps 6.1%: Will It Continue to Soar? - Nasdaq
Wave Life Sciences reports progress in DMD treatment By Investing.com - Investing.com Australia
Wave Aspires To Accelerated Approval In DMD With 48-Week Data - insights.citeline.com
Riding the Wave, exon skipper sails toward DMD filing - BioWorld Online
Sector Update: Health Care Stocks Retreat Wednesday Afternoon - Marketscreener.com
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target By Investing.com - Investing.com South Africa
Jefferies maintains Buy on WAVE Life Sciences stock, $26 target - Investing.com India
Wave Life Sciences Stock Jumps On Positive Data From Muscle Disorder Drug, Plans FDA Submission Next Year - Benzinga
Wave to seek FDA accelerated approval for Duchenne candidate in 2026 - MSN
Wave Life Sciences shares surge on positive DMD trial results By Investing.com - Investing.com Australia
Wave Life Sciences shares surge on positive DMD trial results - Investing.com
Wave Life Sciences reports progress in DMD treatment - Investing.com India
Wave Life Sciences Reports Positive Phase 2 Trial Results - TipRanks
Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD - MarketScreener
Wave Life Sciences Announces Positive Data from FORWARD-53 - GlobeNewswire
Clinical Trial Breakthrough: New DMD Drug Achieves Unprecedented Muscle Recovery - StockTitan
Victory Capital Management Inc. Increases Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Charles Schwab Investment Management Inc. Grows Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences director Christian Henry sells $102,574 in shares By Investing.com - Investing.com South Africa
Wave Life Sciences director Christian Henry sells $102,574 in shares - Investing.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Acquired by Bank of New York Mellon Corp - Defense World
US Bancorp DE Cuts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Arizona State Retirement System Acquires 7,846 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
How To Trade (WVE) - Stock Traders Daily
Wave Life Sciences’ SWOT analysis: RNA editing pioneer’s stock faces pivotal year - Investing.com
Mizuho maintains WAVE Life Sciences Outperform rating - Investing.com India
Reviewing Wave Life Sciences (NASDAQ:WVE) & Rhythm Pharmaceuticals (NASDAQ:RYTM) - Defense World
Paul Bolno Sells 169,025 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) Stock - Defense World
HC Wainwright Cuts Earnings Estimates for Wave Life Sciences - Defense World
Q1 EPS Forecast for Wave Life Sciences Decreased by Analyst - Defense World
Wave Life Sciences (NASDAQ:WVE) Rating Increased to Hold at StockNews.com - Defense World
Wave Life Sciences CEO Paul Bolno sells shares worth $1.62 million - Investing.com Australia
Commit To Purchase Wave Life Sciences At $7.50, Earn 25.6% Annualized Using Options - Nasdaq
Wave Life Sciences (NASDAQ:WVE) Earns “Buy” Rating from HC Wainwright - Defense World
Analysts Set Expectations for WVE Q1 Earnings - Defense World
H.C. Wainwright maintains $22 target on WAVE Life Sciences stock - Investing.com India
Wave Life Sciences’ Earnings Call Highlights Progress and Challenges - TipRanks
Wave Life Sciences Ltd. (NASDAQ:WVE) Q4 2024 Earnings Call Transcript - MSN
Truist maintains Buy rating on WAVE Life Sciences stock, $36 target By Investing.com - Investing.com South Africa
RBC Trims Price Target on Wave Life Sciences to $14 From $15, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Rhumbline Advisers Buys 17,316 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: Revenue Surge Amidst Clinical ... By GuruFocus - Investing.com Canada
Y Intercept Hong Kong Ltd Sells 6,875 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Principal Financial Group Inc. Buys Shares of 248,645 Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
WAVE Life Sciences Ltd (WVE) Q4 2024 Earnings Call Highlights: R - GuruFocus.com
Wave Life Sciences Ltd (WVE) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):